GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

Roche Opts Out of Deal with Maxygen

  • Roche has terminated its co-development and commercialization agreement with Maxygen related to Maxygen's candidate for acute bleeding indications.

    Roche indicated that it was ending the deal based on the inability of the parties to establish an animal model intended to provide preclinical de-risking of the program.

    Under the terms of the initial agreement, Roche and Maxygen were pursuing the development and commercialization of MAXY-VII, a next-generation Factor VII. Upon termination of the agreement, all rights to the product candidates revert back to Maxygen.

    "We are disappointed with Roche's decision to terminate their involvement in the Factor VII program" comments Russell Howard, Maxygen's CEO. "Treatment options for acute bleeding conditions, such as trauma, are clearly needed. We plan to evaluate the situation carefully before determining the next steps for our MAXY-VII program."


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »